Loading stock data…
ZLAB
$21.54-0.10 (-0.46%)
Market ClosedLast close May 1
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zai Lab Limited in the Healthcare sector is trading at $21.54. The stock is currently near its 52-week low of $15.96, remaining 12.7% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why ZLAB maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$21.54
Potential Upside
5%
Whystock Fair Value$22.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$35.34+64.1%
Range$24.00 – $53.00
Fundamentals
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products includ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.70%
Volume
Today's trading volume
212,681
Recent News
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
Asian equities traded in the US as American depositary receipts were tracking moderately higher Thur
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading
Asian equities traded in the US as American depositary receipts were little changed Wednesday mornin
Assessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target Reset
Zai Lab (ZLAB) has been drawing investor attention after recent share price moves, including a loss of 3.9% over the past day and a gain of 21.6% over the past month. See our latest analysis for Zai Lab. Despite the recent 3.9% one day share price decline and a softer 7 day share price return of 13.35%, Zai Lab’s 30 day and year to date share price gains above 20% suggest momentum has recently picked up, even as the 1 year total shareholder return of 32.53% and 5 year total shareholder return...
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call
Zai Lab (NASDAQ:ZLAB) hosted an investor call tied to the 2026 American Association for Cancer Research (AACR) meeting to highlight new data for its DLL3-targeted antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci; ZL-1310) in small cell lung cancer (SCLC) with brain metastases and in extrap
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
Asian equities traded in the US as American depositary receipts were falling sharply Thursday mornin